Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Routes, J. M.
Right arrow Articles by Nakamura, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Routes, J. M.
Right arrow Articles by Nakamura, M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

International Immunology, Vol. 13, No. 10, 1301-1307, October 2001
© 2001 Japanese Society for Immunology

MHC class I molecules on adenovirus E1A-expressing tumor cells inhibit NK cell killing but not NK cell-mediated tumor rejection

John M. Routes1,2,3,4, James C. Ryan5,6, Sharon Ryan1 and Mary Nakamura5,6

1 Department of Medicine, National Jewish Center for Immunology and Respiratory Medicine, Denver, CO 80206, USA
2 Departments of Medicine and
3 Immunology, and
4 Cancer Center, University of Colorado Health Sciences Center, Denver, CO 80262, USA
5 Department of Medicine, University of California at San Francisco, San Francisco, CA 94113, USA
6 Veterans Affairs Medical Center, San Francisco, CA 94121, USA

Correspondence to: Correspondence to: J. M. Routes, National Jewish Center for Immunology and Respiratory Medicine, Department of Medicine, 1400 Jackson Street, Denver, CO 80206, USA

Expression of adenovirus E1A gene products in tumor cells enhances NK cell lysis in vitro and NK-mediated rejection in vivo, despite increasing class I molecules on tumor cells. It is unclear why the increased expression of MHC class I molecules does not appear to confer resistance to killing by NK cells. One possibility is the unique capacity of E1A to sensitize cells to multiple NK cell killing mechanisms including perforin/granzyme, Fas ligand, tumor necrosis factor-{alpha} and TRAIL. To examine this issue, MCA-102-E1A tumor cells (H-2b) that express E1A and are NK sensitive were transfected with H-2Dd, the ligand for the NK inhibitory receptor, Ly49A. Expression of H-2Dd molecules by MCA-102-E1A cells protected them from lysis by a Ly49A+ NK cell clone and Ly49A+ NK cells isolated from C57BL/6 nude mice. In contrast, NK cell-mediated rejection of MCA-102-E1A tumor cells was not inhibited by the expression of H-2Dd molecules, nor was killing by polyclonal populations of NK cells isolated from C57BL/6-nude mice. H-2Dd interacts with several inhibitory Ly49 receptors that are non-clonally expressed on NK cells in C57BL/6 mice: Ly49A (20% of NK cells), Ly49G2 (54% of NK cells) and Ly49C/I (47% of NK cells). Our data indicate that while E1A sensitizes cells to NK cell killing, it does not interfere with signal transduction by inhibitory NK receptors. Therefore, a small population of NK cells that do not express Ly49A, Ly49G2 or Ly49C/I inhibitory receptors are likely responsible for the rejection of MCA-102-E1A-Dd tumor cells in vivo.

Transmitting editor: W. M. Yokoyama


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
JEMHome page
J. M. Routes, S. Ryan, K. Morris, R. Takaki, A. Cerwenka, and L. L. Lanier
Adenovirus serotype 5 E1A sensitizes tumor cells to NKG2D-dependent NK cell lysis and tumor rejection
J. Exp. Med., December 5, 2005; 202(11): 1477 - 1482.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
S. Tekin and P. J. Hansen
Natural Killer-Like Cells in the Sheep: Functional Characterization and Regulation by Pregnancy-Associated Proteins
Experimental Biology and Medicine, October 1, 2002; 227(9): 803 - 811.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.